9HA Stock Chart & Stats
€2.54
€0.04(1.53%)
At close: 4:00 PM EDT
€2.54
€0.04(1.53%)
Day’s Range― - ―
52-Week Range€1.49 - €12.40
Previous CloseN/A
Volume0.00
Average Volume (3M)22.00
Market Cap
€43.26M
Enterprise Value€65.91
Total Cash (Recent Filing)€23.48M
Total Debt (Recent Filing)€14.15M
Price to Earnings (P/E)―
Beta-0.36
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding26,281,881
10 Day Avg. Volume67
30 Day Avg. Volume22
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.07Price Target Upside690.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Potentially Differentiated ImmunotherapyReported complete responses after ELI-002 7P followed by nivolumab suggest the candidate may prime tumors for deeper checkpoint-inhibitor activity. If prospectively validated, this differentiated mechanism could support combination studies and improve Elicio’s competitive position in KRAS-driven pancreatic cancer.
Improved Leverage ProfileThe sharp reduction in debt-to-equity indicates a materially stronger capital structure than in 2025, giving Elicio more flexibility while advancing its pipeline. Although losses remain substantial, lower leverage can reduce balance-sheet strain and improve the company’s ability to fund development through multiple financing options.
Recent Clinical FundingThe $15 million financing provides resources to advance Phase 1 development of ELI-002 7P and support other pipeline work. Continued funding of clinical programs is important for converting early efficacy signals into prospective evidence, potentially preserving strategic value while key trials progress.
Bears Say
No Commercial RevenueElicio has no approved product generating sales, so its operating model remains dependent on clinical development rather than recurring commercial revenue. Until a candidate is approved or partnered on attractive terms, the company lacks internally generated funds to support research, trials, and ongoing corporate costs.
Persistent Cash BurnSizable and largely unchanged operating cash burn means Elicio consumes cash at a scale close to its reported losses while advancing uncommercialized programs. This persistent requirement can force repeated external financing, potentially diluting shareholders or constraining the pace and scope of clinical development.
Phase 2 Execution RiskMissing the primary endpoint is a material validation setback because it weakens confidence that the observed activity will translate across the intended patient population. Post-hoc signals may guide a refined Phase 3 strategy, but they require prospective confirmation and add development uncertainty.
Elicio Therapeutics News
9HA FAQ
What was Elicio Therapeutics’s price range in the past 12 months?
Elicio Therapeutics lowest stock price was €1.49 and its highest was €12.40 in the past 12 months.
What is Elicio Therapeutics’s market cap?
Elicio Therapeutics’s market cap is €43.26M.
When is Elicio Therapeutics’s upcoming earnings report date?
Elicio Therapeutics’s upcoming earnings report date is Mar 26, 2027 which is in 185 days.
How were Elicio Therapeutics’s earnings last quarter?
Elicio Therapeutics released its earnings results on Aug 13, 2026. The company reported -€0.374 earnings per share for the quarter, beating the consensus estimate of -€0.469 by €0.094.
Is Elicio Therapeutics overvalued?
According to Wall Street analysts Elicio Therapeutics’s price is currently Undervalued.
Does Elicio Therapeutics pay dividends?
Elicio Therapeutics does not currently pay dividends.
What is Elicio Therapeutics’s EPS estimate?
Elicio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elicio Therapeutics have?
Elicio Therapeutics has 26,281,881 shares outstanding.
What happened to Elicio Therapeutics’s price movement after its last earnings report?
Elicio Therapeutics reported an EPS of -€0.374 in its last earnings report, beating expectations of -€0.469. Following the earnings report the stock price went up 1.5%.
Which hedge fund is a major shareholder of Elicio Therapeutics?
Currently, no hedge funds are holding shares in DE:9HA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elicio Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€20.07 (690.12% Upside)
€20.07 (690.12% Upside)
Blogger Sentiment
Neutral
DE:9HA Sentiment 50%
Sector Average 63%
Sector Average 63%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Elicio Therapeutics
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
9HA Stock 12 Month Forecast
Average Price Target
€20.07
▲(690.12% Upside)
Technical Analysis
Compugen
―
―
Seres Therapeutics
―
Milestone Pharmaceuticals
―
Actuate Therapeutics, Inc.
―